Scholarlink

<p>Pulmonary arterial hypertension (PAH) is a&#xa0;rare and progressive disease associated with high morbidity and mortality. Modern PAH therapy aims to achieve a&#xa0;low-risk profile and currently includes combination regimens with agents targeting distinct pathophysiological signaling pathways. Recently, new therapies, such as sotatercept have expanded the therapeutic landscape. This article provides an overview of the current treatment algorithm, emphasizing the importance of structured risk stratification, early treatment re-evaluation and timely escalation. It also addresses the management of specific clinical situations, including pregnancy, perioperative care, comorbidities, medication adherence and palliative support. Close follow-up in specialized centers is essential to ensure the success of treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management der pulmonalarteriellen Hypertonie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月12日

查看全文
  • Christian Gerges,
  • Mona Lichtblau

摘要

Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with high morbidity and mortality. Modern PAH therapy aims to achieve a low-risk profile and currently includes combination regimens with agents targeting distinct pathophysiological signaling pathways. Recently, new therapies, such as sotatercept have expanded the therapeutic landscape. This article provides an overview of the current treatment algorithm, emphasizing the importance of structured risk stratification, early treatment re-evaluation and timely escalation. It also addresses the management of specific clinical situations, including pregnancy, perioperative care, comorbidities, medication adherence and palliative support. Close follow-up in specialized centers is essential to ensure the success of treatment.